Literature DB >> 26249040

Left Ventricular Lead Placement Targeted at the Latest Activated Site Guided by Electrophysiological Mapping in Coronary Sinus Branches Improves Response to Cardiac Resynchronization Therapy.

Yanchun Liang1, Haibo Yu1, Weiwei Zhou1, Guoqing Xu1, Y I Sun1, Rong Liu1, Zulu Wang1, Yaling Han1.   

Abstract

INTRODUCTION: Electrophysiological mapping (EPM) in coronary sinus (CS) branches is feasible for guiding LV lead placement to the optimal, latest activated site at cardiac resynchronization therapy (CRT) procedures. However, whether this procedure optimizes the response to CRT has not been demonstrated. This study was to evaluate effects of targeting LV lead at the latest activated site guided by EPM during CRT.
METHODS: Seventy-six consecutive patients with advanced heart failure who were referred for CRT were divided into mapping (MG) and control groups (CG). In MG, the LV lead, also used as a mapping bipolar electrode, was placed at the latest activated site determined by EPM in CS branches. In CG, conventional CRT procedure was performed. Patients were followed for 6 months after CRT.
RESULTS: Baseline characteristics were comparable between the 2 groups. In MG (n = 29), EPM was successfully performed in 85 of 91 CS branches during CRT. A LV lead was successfully placed at the latest activated site guided by EPM in 27 (93.1%) patients. Compared with CG (n = 47), MG had a significantly higher rate (86.2% vs. 63.8%, P = 0.039) of response (>15% reduction in LV end-systolic volume) to CRT, a higher percentage of patients with clinical improvement of ≥2 NYHA functional classes (72.4% vs. 44.7%, P = 0.032), and a shorter QRS duration (P = 0.004).
CONCLUSIONS: LV lead placed at the latest activated site guided by EPM resulted in a significantly greater CRT response, and a shorter QRS duration.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  LV lead position; LV remodeling; cardiac resynchronization therapy; electrophysiological mapping; heart failure

Mesh:

Year:  2015        PMID: 26249040     DOI: 10.1111/jce.12771

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Coronary sinus lead delay index for optimization of coronary sinus lead placement.

Authors:  Mevlüt Koç; Onur Kaypakli; Gökhan Gözübüyük; Durmus Yıldıray Şahin
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-05-30       Impact factor: 1.468

2.  Computational electrophysiology of the coronary sinus branches based on electro-anatomical mapping for the prediction of the latest activated region.

Authors:  Christian Vergara; Simone Stella; Massimiliano Maines; Pasquale Claudio Africa; Domenico Catanzariti; Cristina Demattè; Maurizio Centonze; Fabio Nobile; Alfio Quarteroni; Maurizio Del Greco
Journal:  Med Biol Eng Comput       Date:  2022-06-21       Impact factor: 3.079

3.  Surface electrogram-guided left ventricular lead placement improves response to cardiac resynchronization therapy.

Authors:  Abdulcebbar Şipal; Serdar Bozyel; Müjdat Aktaş; Emir Derviş; Tayyar Akbulut; Onur Argan; Umut Çelikyurt; Dilek Ural; Tayfun Şahin; Ayşen Ağır; Ahmet Vural
Journal:  Anatol J Cardiol       Date:  2018-03       Impact factor: 1.596

4.  Guidewire Method for Measuring Local Left Ventricular Electrical Activation Time During Cardiac Resynchronization Implantation.

Authors:  Seth J Rials; Michele Pershing; Christy Collins
Journal:  J Innov Card Rhythm Manag       Date:  2018-01-15

Review 5.  Optimal site selection and image fusion guidance technology to facilitate cardiac resynchronization therapy.

Authors:  Benjamin J Sieniewicz; Justin Gould; Bradley Porter; Baldeep S Sidhu; Jonathan M Behar; Simon Claridge; Steve Niederer; Christopher A Rinaldi
Journal:  Expert Rev Med Devices       Date:  2018-07-30       Impact factor: 3.166

6.  Electrically guided versus imaging-guided implant of the left ventricular lead in cardiac resynchronization therapy: a study protocol for a double-blinded randomized controlled clinical trial (ElectroCRT).

Authors:  Charlotte Stephansen; Anders Sommer; Mads Brix Kronborg; Jesper Møller Jensen; Kirsten Bouchelouche; Jens Cosedis Nielsen
Journal:  Trials       Date:  2018-11-01       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.